 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...45678910111213141516» |
- | Edurant (rilpivirine) / J&J
New P2 trial: DRIVE-2: Darunavir and Rilpivirine Interactions With Levonorgestrel Implant (clinicaltrials.gov) - Jul 16, 2018
P2, N=60, Not yet recruiting, Sponsor: Makerere University
- | Nexplanon (etonogestrel implant) / Organon, Edurant (rilpivirine) / J&J
New P2 trial: DRIVE-1: Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant (clinicaltrials.gov) - Jul 16, 2018
P2, N=60, Not yet recruiting, Sponsor: Makerere University
- | Edurant (rilpivirine) / J&J
New P4 trial: Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine (clinicaltrials.gov) - Jun 25, 2018
P4, N=28, Recruiting, Sponsor: Chiang Mai University
- |||||||| Edurant (rilpivirine) / J&J
New P3 trial: RISE: A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (clinicaltrials.gov) - Jun 19, 2018
P3, N=100, Not yet recruiting, Sponsor: Johnson & Johnson Pte Ltd
- | Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P1/2 trial: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - Apr 12, 2018
P1/2, N=155, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- || Edurant (rilpivirine) / J&J
Trial completion date, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Mar 30, 2018
P2, N=61, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial completion date: Jun 2024 --> Sep 2027
- ||| Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion date, Trial initiation date: Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine (clinicaltrials.gov) - Mar 7, 2018
P2b, N=244, Active, not recruiting, Sponsor: ViiV Healthcare
Trial completion date: Jun 2024 --> Sep 2027 Trial completion date: Dec 2020 --> Nov 2018 | Initiation date: Aug 2012 --> Aug 2012
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial initiation date, Trial primary completion date, Adverse events: Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (clinicaltrials.gov) - Feb 14, 2018
P=N/A, N=400, Not yet recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Trial completion date: Dec 2020 --> Nov 2018 | Initiation date: Aug 2012 --> Aug 2012 Initiation date: Sep 2016 --> Feb 2018 | Trial primary completion date: Mar 2017 --> Feb 2018
- | Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Trial completion, Enrollment change: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (clinicaltrials.gov) - Feb 1, 2018
P2, N=104, Completed, Sponsor: PATH
Initiation date: Sep 2016 --> Feb 2018 | Trial primary completion date: Mar 2017 --> Feb 2018 Active, not recruiting --> Completed | N=132 --> 104
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial primary completion date: STEREOS: Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=244, Active, not recruiting, Sponsor: Mahidol University
Active, not recruiting --> Completed | N=132 --> 104 Trial primary completion date: Dec 2017 --> Mar 2018
- |||| Edurant (rilpivirine) / J&J
Trial primary completion date: A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 (clinicaltrials.gov) - Jan 23, 2018
P3, N=483, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Enrollment closed: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Oct 6, 2017
P3, N=224, Active, not recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms (clinicaltrials.gov) - Sep 18, 2017
P4, N=40, Completed, Sponsor: St Stephens Aids Trust
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New trial: STEREOS: Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (clinicaltrials.gov) - Aug 15, 2017
P=N/A, N=244, Active, not recruiting, Sponsor: Mahidol University
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: POPARV: Population Pharmacokinetics of Antiretroviral in Children (clinicaltrials.gov) - Jul 4, 2017
P=N/A, N=700, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
New trial: POPARV: Population Pharmacokinetics of Antiretroviral in Children (clinicaltrials.gov) - Jun 20, 2017
P=N/A, N=700, Not yet recruiting, Sponsor: Assistance Publique - H
- || Vocabria (cabotegravir oral) / ViiV Healthcare
Trial primary completion date: LATTE-2: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (clinicaltrials.gov) - Jun 14, 2017
P2b, N=309, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Dec 2015
- ||| Edurant (rilpivirine) / J&J
Enrollment open: A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants (clinicaltrials.gov) - May 24, 2017
P1, N=110, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- | Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment change, Trial termination, Adverse events: DeepSwitch: Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera (clinicaltrials.gov) - Apr 27, 2017
P4, N=25, Terminated, Sponsor: Sheba Medical Center
Not yet recruiting --> Recruiting N=40 --> 25 | Recruiting --> Terminated; no more participants taking atripla
- ||| Edurant (rilpivirine) / J&J
New P1 trial: A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants (clinicaltrials.gov) - Apr 25, 2017
P1, N=110, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Phase classification, Head-to-Head: SALIF: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (clinicaltrials.gov) - Apr 11, 2017
P3b, N=426, Active, not recruiting, Sponsor: Janssen-Cilag International NV
N=40 --> 25 | Recruiting --> Terminated; no more participants taking atripla Phase classification: P3 --> P3b
- |||| Edurant (rilpivirine) / J&J
Trial primary completion date: A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 (clinicaltrials.gov) - Feb 15, 2017
P3, N=483, Active, not recruiting, Sponsor: Janssen R&D Ireland
Phase classification: P3 --> P3b Trial primary completion date: Dec 2016 --> Dec 2017
- ||||||| Edurant (rilpivirine) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Intelence (etravirine) / J&J
Trial completion, Trial primary completion date: A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women (clinicaltrials.gov) - Feb 15, 2017
P3, N=77, Completed, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016
- Trial primary completion date: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Jan 4, 2017
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016 Trial primary completion date: Dec 2016 --> Aug 2017
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment closed: SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms (clinicaltrials.gov) - Nov 29, 2016
P4, N=40, Active, not recruiting, Sponsor: St Stephens Aids Trust
Trial primary completion date: Dec 2016 --> Aug 2017 Recruiting --> Active, not recruiting
- Trial primary completion date: Characterization of Acute and Recent HIV-1 Infections in Zurich. (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=2016, Recruiting, Sponsor: University of Zurich
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jan 2025
- ||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Trial completion: Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (clinicaltrials.gov) - Oct 26, 2016
P1, N=118, Completed, Sponsor: ViiV Healthcare
Trial primary completion date: Dec 2015 --> Jan 2025 Recruiting --> Completed
- || Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Enrollment change: Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (clinicaltrials.gov) - Oct 18, 2016
P1, N=118, Recruiting, Sponsor: ViiV Healthcare
Recruiting --> Completed N=86 --> 118
- Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
New trial, Adverse events: Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (clinicaltrials.gov) - Aug 28, 2016
P=N/A, N=400, Not yet recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- || Edurant (rilpivirine) / J&J
Trial primary completion date, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Aug 24, 2016
P2, N=56, Recruiting, Sponsor: Janssen Sciences Ireland UC
N=86 --> 118 Trial primary completion date: Oct 2023 --> Jan 2020
- ||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Enrollment open: Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (clinicaltrials.gov) - Jul 11, 2016
P1, N=86, Recruiting, Sponsor: ViiV Healthcare
Trial primary completion date: Oct 2023 --> Jan 2020 Not yet recruiting --> Recruiting
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open, HEOR: Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) - Jun 30, 2016
P4, N=150, Recruiting, Sponsor: Juan A. Arnaiz
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Edurant (rilpivirine) / J&J
Trial completion: A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics (clinicaltrials.gov) - Jun 15, 2016
P1, N=62, Completed, Sponsor: Janssen Infectious Diseases BVBA
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Edurant (rilpivirine) / J&J
Trial completion: Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet (clinicaltrials.gov) - Jun 11, 2016
P1, N=32, Completed, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed Recruiting --> Completed
- ||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
New P1 trial: Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) (clinicaltrials.gov) - Apr 18, 2016
P1, N=86, Not yet recruiting, Sponsor: ViiV Healthcare
- Edurant (rilpivirine) / J&J
Trial primary completion date: DRV/r + RPV QD: Efficacy and Toxicity Reduction (clinicaltrials.gov) - Mar 30, 2016
P3, N=132, Recruiting, Sponsor: Ospedale L. Sacco
Recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- |||| Edurant (rilpivirine) / J&J
Enrollment open, Trial primary completion date, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Feb 22, 2016
P2, N=56, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2014 --> Oct 2023
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment open, Trial initiation date: SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms (clinicaltrials.gov) - Feb 21, 2016
P4, N=40, Recruiting, Sponsor: St Stephens Aids Trust
Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2014 --> Oct 2023 Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015
- |||| Edurant (rilpivirine) / J&J
Trial primary completion date: A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 (clinicaltrials.gov) - Feb 4, 2016
P3, N=483, Active, not recruiting, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- | Trial completion: 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients (clinicaltrials.gov) - Jan 27, 2016
P3, N=100, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Edurant (rilpivirine) / J&J
Enrollment open: Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet (clinicaltrials.gov) - Nov 30, 2015
P1, N=32, Recruiting, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Edurant (rilpivirine) / J&J
Enrollment change, IO biomarker: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Nov 17, 2015
P2, N=56, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting N=36 --> 56
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants (clinicaltrials.gov) - Nov 8, 2015
P4, N=8, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=36 --> 56 Not yet recruiting --> Completed
- |||| Edurant (rilpivirine) / J&J
Enrollment open: A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (clinicaltrials.gov) - Oct 29, 2015
P2, N=100, Recruiting, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Edurant (rilpivirine) / J&J
Enrollment open: A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Recruiting, Sponsor: Janssen Infectious Diseases BVBA
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Edurant (rilpivirine) / J&J
New P1 trial: Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet (clinicaltrials.gov) - Sep 28, 2015
P1, N=32, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- || Vocabria (cabotegravir oral) / ViiV Healthcare
Trial primary completion date: LATTE-2: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (clinicaltrials.gov) - Sep 24, 2015
P2b, N=310, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2020 --> Aug 2015
- Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Enrollment closed: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (clinicaltrials.gov) - Sep 24, 2015
P2, N=132, Active, not recruiting, Sponsor: PATH
Trial primary completion date: Dec 2020 --> Aug 2015 Recruiting --> Active, not recruiting
- ||| Edurant (rilpivirine) / J&J
New P1 trial: A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics (clinicaltrials.gov) - Sep 14, 2015
P1, N=60, Not yet recruiting, Sponsor: Janssen Infectious Diseases BVBA
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P4 trial: A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants (clinicaltrials.gov) - Aug 20, 2015
P4, N=8, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.